Abcam, ab251470, Anti-MAGEC1 antibody [EPR18067] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal MAGEC1 antibody. Carrier free. Suitable for WB, IHC-P and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR18067,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251470 is the carrier-free version of
ab207304
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MAGEC1 also known as Melanoma Antigen Family C1 is a protein with a molecular weight of approximately 127 kDa. Researchers have identified MAGEC1 in various tissues; however its expression strongly associates with certain types of cancer cells notably multiple myeloma. The protein belongs to the MAGE (Melanoma Antigen Genes) family which shows similarities in structure and function across its members.
Biological function summary
Many studies focus on the role of MAGEC1 in the regulation of cell survival and proliferation. MAGEC1 tends to enhance tumor growth by inhibiting apoptotic pathways therefore favoring cancer cell survival. This regulation occurs through interaction with other proteins such as members of the p53 family and histone deacetylases (HDACs). MAGEC1 lacks the ability to function independently and often forms complexes with these proteins to modulate gene expression and cellular pathways.
Pathways
Investigations reveal that MAGEC1 plays a significant role in oncogenic pathways especially through the p53 signaling pathway. This protein directly interacts with tumor suppressor p53 inhibiting its function and altering the normal apoptosis mechanism. MAGEC1 also connects with HDACs to influence epigenetic modifications further impacting cell cycle regulation and accounting for the resistant phenotype observed in cancer cells.
MAGEC1 bears significant relevance to multiple myeloma and breast cancer. Elevated MAGEC1 levels are linked to poor prognosis in multiple myeloma potentially through interaction with proteins such as HSP70 which assists in its stability and function. Additionally MAGEC1 presence in breast cancer highlights its role in tumor progression and potential as a target for therapeutic interventions posing it as a candidate for cancer immunotherapy research.